Health – KEYTRUDA® (pembrolizumab) Now Registered to Treat Certain Patients with Malignant Pleural Mesothelioma, Biliary Tract Carcinoma and Merkel Cell Carcinoma1
Source: Merck & Co Auckland, New Zealand, March 28th, 2025 – MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK) announced today that KEYTRUDA is now registered to treat patients with the following cancers: MalignantPleural Mesothelioma (MPM): KEYTRUDA as a first-line treatment may be combined with chemotherapy medicines to treat MPM, a … Read more